Compare Enbridge Inc (ENB) vs GSK plc (GSK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enbridge Inc vs GSK plc — how do they compare? Enbridge Inc trades at $46.47 (market cap $103.38B), while GSK plc trades at $46.6 (market cap $91.88B). The key difference: Enbridge Inc and GSK plc are close in size by market cap, and Enbridge Inc pays the higher dividend (6.02%). Which is the better fit depends on your goals — on Pluang, investors hold Enbridge Inc for 91 Days and GSK plc for 93 Days on average.
| ENB | GSK | |
|---|---|---|
Market Cap | $103.38B | $91.88B |
Volume | 3,684,305 | 7,730,529 |
Sector | Energy | Health |
52-Week High | $58.04 | $61.18 |
52-Week Low | $45.23 | $43.24 |
Typical Hold Time | 91 Days | 93 Days |
Enterprise Value | $185.39B | $111.88B |
Dividend Yield | 6.02% | 3.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENB trades at $46.465, up 1.25% today, with a bearish technical signal but strong fundamentals including three consecutive quarterly EPS beats and a 6% dividend yield. Revenue grew to $65.19B in 2025, with net income of $7.49B, though profit margins have fluctuated. Analyst consensus is mixed with a $61.63 price target, while recent news highlights its stable cash flow and expansion into renewables.
The outlook balances a high yield and growth projects against interest rate sensitivity and debt levels near 49% of assets. Upside exists if execution on the $41B backlog drives earnings, but macroeconomic pressures and technical weakness pose near-term risks for shareholders.
GSK trades at $46.45, down 1.21% with bearish technical signals. The company shows strong fundamentals with revenue growth to $32.67B in 2025 and consistent earnings beats. Valuation metrics appear reasonable with P/E of 14.89 and EV/EBITDA of 8.75. Recent developments include strategic oncology partnerships and a $750M cancer therapy acquisition, positioning for long-term growth despite near-term technical weakness.
GSK presents a mixed outlook with strong profitability and pipeline expansion offset by technical bearishness and HIV patent concerns. The company's 29.73% ROE and recent earnings outperformance support investment appeal, while the bearish moving average signal and competitive pressures warrant caution. Analyst consensus leans hold with 55% neutral rating, suggesting balanced risk-reward for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Enbridge Inc
Enbridge owns extensive midstream assets that transport hydrocarbons across the U.S. and Canada. Its pipeline network consists of the Canadian Mainline system, regional oil sands pipelines, and natural gas pipelines. The company also owns and operates a regulated natural gas utility and Canada's largest natural gas distribution company. Finally, the firm has a small renewables portfolio primarily focused on onshore and offshore wind projects.
Read more on ENB →About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →
